Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Phosphomannose isomerase (PMI) deficiency is the cause of a new type of carbohydrate-deficient glycoprotein syndrome (CDGS). The disorder is caused by mutations in the PMI1 gene. The clinical phenotype is characterized by protein-losing enteropathy, while neurological manifestations prevailing in other types of CDGS are absent. Using standard diagnostic procedures, the disorder is indistinguishable from CDGS type Ia (phosphomannomutase deficiency). Daily oral mannose administration is a successful therapy for this new type of CDG syndrome classified as CDGS type Ib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphomannomutase deficiency is a cause of carbohydrate‐deficient glycoprotein syndrome type I
(1995) · FEBS Letters · doi:10.1016/0014-5793(95)01357-1 · Cited by 359 · cited 6×
“ing to a procedure by van Schaftingen and Jaeken (6).”
BackgroundMethodInfluentialJaeken, J., Vanderschueren-Lodeweyckx, M., Casaer, P., Snoeck, L., Corbeel, L., Eggermont, E., & Eeckels, R. (1980) · Pediatric Research · doi:10.1203/00006450-198002000-00117 · Cited by 287 · cited 1×
“(1) Hexokinase; (2) glucose 6-phosphate dehydrogenase; (3) phosphoglucose isomerase; (4) phosphomannose isomerase; (5) phosphomannomutase; (6) GDPmannose synthase.”
Panneerselvam, K., & Freeze, H. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118570 · Cited by 146 · cited 1×
“Based on studies showing that mannose could correct abnormal glycosylation in CDGS type Ia fibroblasts (15), mannose therapy was initiated and followed up for 11 mo.”
BackgroundSelf-citationThe X-ray crystal structure of phosphomannose isomerase from Candida albicans at 1.7 Å resolution
Cleasby, A., Wonacott, A. J., Skarzynski, T. J., Hubbard, R. E., Davies, G. J., Proudfoot, A. E. I., Bernard, A. R., Payton, M. A., & Wells, T. N. C. (1996) · Nature Structural Biology · doi:10.1038/nsb0596-470 · Cited by 115
Alton, G., Kjærgaard, S., Etchison, J. R., Skovby, F., & Freeze, H. H. (1997) · Biochemical and Molecular Medicine · doi:10.1006/bmme.1997.2574 · Cited by 111 · cited 1×
“In accordance with previous human ingestion studies (19), mannose was given orally in an initial dose of 100 mg/kg body wt three times a day.”
Self-citationCarbohydrate-Deficient Glycoprotein Syndrome - A Fourth Subtype
Stibler, H., Stephani, U., & Kutsch, U. (1995) · Neuropediatrics · doi:10.1055/s-2007-979762 · Cited by 92 · cited 1×
“(1) Hexokinase; (2) glucose 6-phosphate dehydrogenase; (3) phosphoglucose isomerase; (4) phosphomannose isomerase; (5) phosphomannomutase; (6) GDPmannose synthase.”
Purification cDNA cloning and heterologous expression of human phosphomannose isomerase
PROUDFOOT, A. E. I., TURCATTI, G., WELLS, T. N. C., PAYTON, M. A., & SMITH, D. J. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb19954.x · Cited by 86 · cited 3×
“The sequence of the human PMI cDNA (10) was used to design primers for PCR amplification.”
BackgroundMethodInfluentialCarbohydrate-Deficient Glycoprotein (CDG) Syndrome - A New Variant, Type III
Stibler, H., Westerberg, B., Hanefeld, F. A., & Hagberg, B. (1993) · Neuropediatrics · doi:10.1055/s-2008-1071513 · Cited by 71 · cited 1×
“(1) Hexokinase; (2) glucose 6-phosphate dehydrogenase; (3) phosphoglucose isomerase; (4) phosphomannose isomerase; (5) phosphomannomutase; (6) GDPmannose synthase.”
Human Fibroblasts Prefer Mannose over Glucose as a Source of Mannose for N-Glycosylation
Panneerselvam, K., Etchison, J. R., & Freeze, H. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.37.23123 · Cited by 70
Self-citationA novel Saccharomyces cerevisiae secretory mutant possesses a thermolabile phosphomannose isomerase
Payton, M. A., Rheinnecker, M., Klig, L. S., Detiani, M., & Bowden, E. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.6.2006-2010.1991 · Cited by 70 · cited 1×
“Phenotypic correction of the PMI deficiency in yeast was achieved by supplying 5 mM mannose together with glucose (20).”
Method
Cited by
Glycosylation in Cellular Mechanisms of Health and Disease
Ohtsubo, K., & Marth, J. D. (2006) · Cell · doi:10.1016/j.cell.2006.08.019 · Cited by 2,788
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
A Genetic Approach to Mammalian Glycan Function
Lowe, J. B., & Marth, J. D. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161809 · Cited by 594
Genetic defects in the human glycome
Freeze, H. H. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1894 · Cited by 467
“cgi?id=602579">CDG-Ib , which is caused by mutations in phosphomannose isomerase ( MPI ) have a milder phenotype than those with CDG-Ia, without developmental delay or psychomotor retardation, and respond to dietary therap”
BackgroundSelf-citationLehle, L., Strahl, S., & Tanner, W. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200601645 · Cited by 316
Marquardt, T., & Denecke, J. (2003) · European Journal of Pediatrics · doi:10.1007/s00431-002-1136-0 · Cited by 290
“CDG-Ia CDGS Ia Phosphomannomutase 2 PMM 2 [137] CDG-Ib CDGS Ib Phosphomannose Isomerase PMI [106] CDG-Ic CDGS Ic/V Dol-P-Glc: Man9GlcNAc2-Glucosyltransferase hALG6 [63, 82] CDG-Id CDGS IV Dol-P-Man: Man5GlcNAc2-Mannosyltransferase hALG3/Not56L [83] CDG-Ie CDGS IV Dol-P-Man Synthase 1 DPM 1 [65, 79] CDG-If – MPDU1/Lec3…”
BackgroundResultInfluentialSelf-citationMultiple Phenotypes in Phosphoglucomutase 1 Deficiency
Tegtmeyer, L. C., Rust, S., van Scherpenzeel, M., Ng, B. G., Losfeld, M.-E., Timal, S., Raymond, K., He, P., Ichikawa, M., Veltman, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1206605 · Cited by 284
Self-citationCorrection of leukocyte adhesion deficiency type II with oral fucose
Marquardt, T., Lühn, K., Srikrishna, G., Freeze, H. H., Harms, E., & Vestweber, D. (1999) · Blood · doi:10.1182/blood.v94.12.3976 · Cited by 280
Self-citationMannose ameliorates experimental colitis by protecting intestinal barrier integrity
Dong, L., Xie, J., Wang, Y., Jiang, H., Chen, K., Li, D., Wang, J., Liu, Y., He, J., Zhou, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32505-8 · Cited by 261
Altered glycan structures: the molecular basis of congenital disorders of glycosylation
Freeze, H. H., & Aebi, M. (2005) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2005.08.010 · Cited by 250
Self-citationMannose metabolism: More than meets the eye
Sharma, V., Ichikawa, M., & Freeze, H. H. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.06.021 · Cited by 238
“3HOH release provides an approximate measure of [2-3H]-Man catabolism and has been used as a sensitive in vitro and live cell measure of MPI activity [2,39].”
BackgroundMethodSelf-citationCongenital disorders of glycosylation
Chang, I. J., He, M., & Lam, C. T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.45 · Cited by 235
“com vomiting, significant hypoglycemia, failure to thrive, potentially life-threatening protein-wasting enteropathy, liver fibrotic changes, and bile duct dilatation (45-51).”
BackgroundPerspectives on Glycosylation and Its Congenital Disorders
Ng, B. G., & Freeze, H. H. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.03.002 · Cited by 228
“The first CDG to be efficiently treated was MPI-CDG, which simply required dietary supplementation with Dmannose [81].”
MethodSelf-citationUnderstanding Human Glycosylation Disorders: Biochemistry Leads the Charge
Freeze, H. H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.429274 · Cited by 213
“However, modest daily supplements of mannose correct most of the patients’ glycosylation deficiencies (40, 41).”
BackgroundSelf-citationde Lonlay, P., Seta, N., Barrot, S., Chabrol, B., Drouin, V, Gabriel, B. M., Journel, H., Kretz, M., Laurent, J., Le Merrer, M., et al. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.1.14 · Cited by 220
Self-citationCongenital Disorders of Glycosylation: A Review
Grünewald, S., Matthijs, G., & Jaeken, J. (2002) · Pediatric Research · doi:10.1203/00006450-200211000-00003 · Cited by 212
Congenital Disorders of Glycosylation
Patterson, M. C. (2017) · Oxford Medicine Online · doi:10.1093/med/9780199937837.003.0066 · Cited by 210
Traffic Jams II: An Update of Diseases of Intracellular Transport
Aridor, M., & Hannan, L. A. (2002) · Traffic · doi:10.1034/j.1600-0854.2002.31103.x · Cited by 205
Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease
Li, A., Davila, S., Furu, L., Qian, Q., Tian, X., Kamath, P. S., King, B. F., Torres, V. E., & Somlo, S. (2003) · The American Journal of Human Genetics · doi:10.1086/368295 · Cited by 193
“Interestingly, autosomal recessive carbohydratedeficient glycoprotein syndrome type Ib is associated with congenital hepatic fibrosis and results from nearly complete absence of phosphomannose isomerase, the enzyme needed to maintain the dolichol pyrophosphateoligosaccharide pool (Jaeken et al. 1998; Niehues et al. 19…”
BackgroundGenetic remodeling of protein glycosylation in vivo induces autoimmune disease
Chui, D., Sellakumar, G., Green, R. S., Sutton-Smith, M., McQuistan, T., Marek, K. W., Morris, H. R., Dell, A., & Marth, J. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1142 · Cited by 192
Congenital Disorders of Glycosylation
Jaeken, J., & Matthijs, G. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.129 · Cited by 189
Haeuptle, M. A., & Hennet, T. (2009) · Human Mutation · doi:10.1002/humu.21126 · Cited by 185
Evaluation of protein safety in the context of agricultural biotechnology
Delaney, B., Astwood, J. D., Cunny, H., Conn, R. E., Herouet-Guicheney, C., MacIntosh, S., Meyer, L. S., Privalle, L., Gao, Y., Mattsson, J., et al. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.01.045 · Cited by 176
Mannose Alters Gut Microbiome, Prevents Diet-Induced Obesity, and Improves Host Metabolism
Sharma, V., Smolin, J., Nayak, J., Ayala, J. E., Scott, D. A., Peterson, S. N., & Freeze, H. H. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.064 · Cited by 176
“Although the expression of phosphomannomutase that diverts mannose-6-phosphate to glycosylation was unaltered by mannose, MPI that catabolizes mannose through glycolysis was 1.25-fold higher in HFD+M versus HFD group (n = 8; p = 0.009).”
BackgroundSelf-citationKim, S., Westphal, V., Srikrishna, G., Mehta, D. P., Peterson, S., Filiano, J., Karnes, P. S., Patterson, M. C., & Freeze, H. H. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7302 · Cited by 177
“In contrast, mannose has been quite successful in treating patients with PMI deficiency (6, 38, 39).”
BackgroundMethodInfluentialSelf-citationImbach, T., Schenk, B., Schollen, E., Burda, P., Stutz, A., Grünewald, S., Bailie, N. M., King, M. D., Jaeken, J., Matthijs, G., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8691 · Cited by 176
“The PMI gene is responsible for CDG-Ib and its characteristic deficiency in phosphomannose isomerase (5, 6).”
BackgroundJaeken, J., Matthijs, G., Saudubray, J.-M., Dionisi-Vici, C., Bertini, E., de Lonlay, P., Henri, H., Carchon, H., Schollen, E., & Van Schaftingen, E. (1998) · The American Journal of Human Genetics · doi:10.1086/301873 · Cited by 177
Ostrow, A. M., Freeze, H., & Rychik, J. (2006) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2006.02.048 · Cited by 171
Self-citationCongenital disorders of glycosylation: genetic model systems lead the way
Aebi, M. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)01925-0 · Cited by 167
Kurtoglu, M., Maher, J. C., & Lampidis, T. J. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1714 · Cited by 163
Update and perspectives on congenital disorders of glycosylation
Freeze, H. H. (2001) · Glycobiology · doi:10.1093/glycob/11.12.129r · Cited by 156
“…through the intestine), diarrhea, cyclic vomiting, liver dysfunction, and hepatic fibrosis; surprisingly there is no mental retardation, neuropathy, or ataxia (de Koning et al., 1998a,b, 2000; de Lonlay et al., 1998; Jaeken et al., 1998; Niehues et al., 1998; Babovic-Vuksanovic et al., 1999).”
BackgroundInfluentialSelf-citationBode, L., Salvestrini, C., Park, P. W., Li, J., Esko, J. D., Yamaguchi, Y., MURCH, S. H., & Freeze, H. H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32335 · Cited by 153
“CDG-Ib patients, whose N -glycosylation is impaired due to genetic phosphomannose isomerase deficiency, develop hepatic fibrosis and portal hypertension (4, 5, 19).”
Self-citationControl of T Cell-mediated Autoimmunity by Metabolite Flux to N-Glycan Biosynthesis
Grigorian, A., Lee, S.-U., Tian, W., Chen, I.-J., Gao, G., Mendelsohn, R., Dennis, J. W., & Demetriou, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701890200 · Cited by 146
Clinical approach to inherited metabolic disorders in neonates: an overview
Saudubray, J., Nassogne, M., de Lonlay, P., & Touati, G. (2002) · Seminars in Neonatology · doi:10.1053/siny.2001.0083 · Cited by 147
ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan
Gerin, I., Ury, B., Breloy, I., Bouchet-Seraphin, C., Bolsée, J., Halbout, M., Graff, J., Vertommen, D., Muccioli, G. G., Seta, N., et al. (2016) · Nature Communications · doi:10.1038/ncomms11534 · Cited by 145
Congenital disorders of glycosylation: Still “hot” in 2020
Ondrušková, N., Čechová, A., Hansíková, H., Honzík, T., & Jaeken, J. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129751 · Cited by 143
Congenital disorders of glycosylation (CDG): It's all in it!
Jaeken, J. (2003) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1024431131208 · Cited by 177
“In fact, the response to a mannose trial led to the hypothesis of PMI de¢ciency in these patients (Jaeken et al 1998; Niehues et al 1998).”
BackgroundMPDU1 mutations underlie a novel human congenital disorder of glycosylation, designated type If
Schenk, B., Imbach, T., Frank, C. G., Grubenmann, C. E., Raymond, G. V., Hurvitz, H., Raas-Rotschild, A., Luder, A. S., Jaeken, J., Berger, E. G., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200113419 · Cited by 141
Körner, C., Knauer, R., Stephani, U., Marquardt, T., Lehle, L., & FIGURA, K. V. (1999) · The EMBO Journal · doi:10.1093/emboj/18.23.6816 · Cited by 140
Self-citationWang, Y., Tan, J., Sutton-Smith, M., Ditto, D., Panico, M., Campbell, R. M., Varki, N. M., Long, J. M., Jaeken, J., Levinson, S. R., et al. (2001) · Glycobiology · doi:10.1093/glycob/11.12.1051 · Cited by 134
“For example, an inherited genetic mutation in the glycosyltransferase gene Galgt2 alters cell lineage expression and in this manner creates a novel function involving the homeostasis of von Willebrand factor in circulation ( Mohlke et al., 1999 ).”
BackgroundLübke, T., von Figura, K., Körner, C., & Marquardt, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.25986 · Cited by 134
Self-citationThiel, C., Schwarz, M., Peng, J., Grzmil, M., Hasilik, M., Braulke, T., Kohlschütter, A., FIGURA, K. V., Lehle, L., & Körner, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302850200 · Cited by 148
Self-citationA mutation in the human MPDU1 gene causes congenital disorder of glycosylation type If (CDG-If)
Kranz, C., Denecke, J., Lehrman, M. A., Ray, S., Kienz, P., Kreissel, G., Šagi, D., Peter‐Katalinić, J., Freeze, H. H., Schmid, T., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13635 · Cited by 131
“One- and two-dimensional electrophoresis was done as described (8).”
BackgroundMethodSelf-citationHanßke, B., Thiel, C., Lübke, T., Hasilik, M., Höning, S., Peters, V., Heidemann, P. H., Hoffmann, G. F., Berger, E. G., FIGURA, K. V., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14010 · Cited by 157
Self-citationde Lonlay, P., Cuer, M., Vuillaumier‐Barrot, S., Beaune, G., Castelnau, P., Kretz, M., Durand, G., Saudubray, J., & Séta, N. (1999) · The Journal of Pediatrics · doi:10.1016/s0022-3476(99)70139-3 · Cited by 129
Diseases of glycosylation beyond classical congenital disorders of glycosylation
Hennet, T. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.02.001 · Cited by 127
Chantret, I., Dupré, T., Delenda, C., Bucher, S., Dancourt, J., Barnier, A., Charollais, A., Héron, D., Bader‐Meunier, B., Danos, O., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203285200 · Cited by 136
Leukocyte adhesion deficiency II syndrome, a generalized defect in fucose metabolism
Marquardt, T., Brune, T., Lühn, K., Zimmer, K.-P., Körner, C., Fabritz, L., van der Werft, N., Vormoor, J., Freeze, H. H., Louwen, F., et al. (1999) · The Journal of Pediatrics · doi:10.1016/s0022-3476(99)70281-7 · Cited by 125
“4 The remaining 10% is made by a fucose salvage pathway from degraded glycoconjugates or from exogenous fucose.”
BackgroundSelf-citationde Lonlay, P., & Séta, N. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.11.012 · Cited by 134
“This fibrosis is reported in all patients but one (8) where liver biopsy was performed (3, 5, 6, 13, 15).”
BackgroundMethodInfluentialDolichol-phosphate mannose synthase: Structure, function and regulation
Maeda, Y., & Kinoshita, T. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.03.005 · Cited by 119
Congenital disorders of glycosylation: a concise chart of glycocalyx dysfunction
Hennet, T., & Cabalzar, J. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.03.002 · Cited by 117
Imbach, T., Burda, P., Kuhnert, P., Wevers, R. A., Aebi, M., Berger, E. G., & Hennet, T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6982 · Cited by 116
Körner, C., Knauer, R., Holzbach, U., Hanefeld, F., Lehle, L., & von Figura, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13200 · Cited by 116
Self-citationMarques‐da‐Silva, D., Ferreira, V. D. R., Monticelli, M., Janeiro, P. C. R. B., Videira, P. A., Witters, P., Jaeken, J., & Cassiman, D. M. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-0012-4 · Cited by 111
“In 1998, MPI-CDG was reported as a pure hepatic and gastrointestinal CDG, thus lacking neurological symptoms (de Koning et al 1998; Jaeken et al 1998; Niehues et al 1998).”
BackgroundDeRossi, C., Bode, L., Eklund, E. A., Zhang, F., Davis, J. A., Westphal, V., Wang, L., Borowsky, A. D., & Freeze, H. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511982200 · Cited by 120
Self-citationGlycosylation diseases: Quo vadis?
Schachter, H., & Freeze, H. H. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.11.002 · Cited by 111
Self-citationLübbehusen, J., Thiel, C., Rind, N., Ungár, D., Prinsen, B. H. C. M. T., de Koning, T. J., van Hasselt, P. M., & Körner, C. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq278 · Cited by 110
Self-citationCongenital disorders of glycosylation
Jaeken, J. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59565-2.00044-7 · Cited by 122
Ferreira, C. R., & van Karnebeek, C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64029-1.00022-9 · Cited by 159
CDG Therapies: From Bench to Bedside
Brasil, S., Pascoal, C., Francisco, R., Marques‐da‐Silva, D., Andreotti, G., Videira, P. A., Morava, É., Jaeken, J., & Ferreira, V. D. R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051304 · Cited by 117
“Man supplementation was first tried in a patient in 1998 [49].”
BackgroundBurda, P., Borsig, L., de Rijk-van Andel, J., Wevers, R., Jaeken, J., Carchon, H., Berger, E. G., & Aebi, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2266 · Cited by 98
“Recently, the CDGS type Ib was described and assigned to a deficiency in phosphomannoisomerase, an enzyme required in GDP-mannose biosynthesis before phosphomannomutase (19).”
BackgroundResultWestphal, V., MURCH, S. H., Kim, S., Srikrishna, G., WINCHESTER, B. G., Day, R. M., & Freeze, H. H. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64830-4 · Cited by 103
“For instance, PMI-deficient CDG-Ib patients have severe diarrhea, vomiting, and PLE.14–16 Small intestine biopsies show partial villus atrophy and the enterocyte endoplasmic reticulum is distended and engorged with insoluble precipitated proteins associated with the abundant chaperone BiP.14 Oral mannose therapy effec…”
BackgroundSelf-citationSevere hypoglycemia as a presenting symptom of carbohydrate-deficient glycoprotein syndrome
Babovic‐Vuksanovic, D., Patterson, M. C., Schwenk, W. F., O’Brien, J. F., Vockley, J. E., Freeze, H. H., Mehta, D. P., & Michels, V. V. (1999) · The Journal of Pediatrics · doi:10.1016/s0022-3476(99)70103-4 · Cited by 94
Self-citationSLC39A8 deficiency: biochemical correction and major clinical improvement by manganese therapy
Park, J. H., Hogrebe, M., Fobker, M., Brackmann, R., Fiedler, B. J., Reunert, J., Rust, S., Tsiakas, K., Santer, R., Grüneberg, M., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.106 · Cited by 99
Self-citationScreening and diagnosis of congenital disorders of glycosylation
Marklová, E., & Albahri, Z. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.07.002 · Cited by 101
Chantret, I., Dancourt, J., Dupré, T., Delenda, C., Bucher, S., Vuillaumier‐Barrot, S., de Baulny, H. O., Peletan, C., Danos, O., Séta, N., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211950200 · Cited by 90
Schwarz, M., Thiel, C., Lübbehusen, J., Dorland, B., de Koning, T. J., FIGURA, K. V., Lehle, L., & Körner, C. (2004) · The American Journal of Human Genetics · doi:10.1086/382492 · Cited by 89
“IEF and SDS/PAGE of serum transferrin were performed as described elsewhere (Niehues et al. 1998).”
MethodSelf-citationDörre, K., Olczak, M., Wada, Y., Sosicka, P., Grüneberg, M., Reunert, J., Kurlemann, G., Fiedler, B., Biskup, S., Hörtnagel, K., et al. (2015) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-015-9828-6 · Cited by 88
“Immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) To identify missing or truncated carbohydrate side chains of serum transferrin, immunoprecipitation, and SDS-PAGEwere performed as described previously (Niehues et al 1998).”
MethodSelf-citationHarms, H. K., Zimmer, K., Kurnik, K., Bertele‐Harms, R. M., Weidinger, S., & Reiter, K. (2002) · Acta Paediatrica · doi:10.1080/080352502760311566 · Cited by 93
Self-citationCongenital Disorder of Glycosylation Type Ik (CDG-Ik): A Defect of Mannosyltransferase I
Kranz, C., Denecke, J., Lehle, L., Sohlbach, K., Jeske, S., Meinhardt, F., Rossi, R., Gudowius, S., & Marquardt, T. (2004) · The American Journal of Human Genetics · doi:10.1086/382493 · Cited by 88
“…basic researchers, as well as for physicians; it is more demanding than ever to use the understanding of the molecular bases of the diseases to develop effective treatments for them as has been done so far only for CDG-Ib and CDG-IIc (Niehues et al. 1998; Marquardt et al. 1999; Lühn et al. 2001).”
BackgroundSelf-citationDamen, G. M., de Klerk, H., Huijmans, J. G. M., den Hollander, J., & Sinaasappel, M. (2004) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/j.1536-4801.2004.tb12163.x · Cited by 97
Ozen, A. O., & Lenardo, M. J. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2301594 · Cited by 90
Westphal, V., Kjærgaard, S., Davis, J. A., Peterson, S. M., Skovby, F., & Freeze, H. H. (2001) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2001.3161 · Cited by 81
Self-citationThe Role of Phosphomannose Isomerase in Leishmania mexicana Glycoconjugate Synthesis and Virulence
Garami, A., & Ilg, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009226200 · Cited by 87
Oral D-galactose supplementation in PGM1-CDG
Wong, S., Gadomski, T., van Scherpenzeel, M., Honzík, T., Hansíková, H., Holmefjord, K. S. B., Mork, M., Bowling, F. G., Sykut‐Cegielska, J., Koch, D., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.41 · Cited by 80
Glycans Instructing Immunity: The Emerging Role of Altered Glycosylation in Clinical Immunology
Lyons, J. J., Milner, J. D., & Rosenzweig, S. D. (2015) · Frontiers in Pediatrics · doi:10.3389/fped.2015.00054 · Cited by 93
“A patient with MPI deficiency was treated with 100mg/kg three times daily, increased after 8months to 150mg/kg five times daily (64).”
Leroy, J. G. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000246802.57692.ea · Cited by 78
Golgi linked protein glycosylation and associated diseases
Ungár, D. (2009) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2009.03.004 · Cited by 86
Disorders in protein glycosylation and potential therapy: Tip of an iceberg?
Freeze, H. H. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70096-4 · Cited by 85
Self-citationStudies of mannose metabolism and effects of long-term mannose ingestion in the mouse
Davis, J. A., & Freeze, H. H. (2001) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(01)00183-0 · Cited by 84
Self-citationIncorporation of orally applied 13C-galactose into milk lactose and oligosaccharides
Rudloff, S., Obermeier, S., Borsch, C., Pohlentz, G., Hartmann, R., Brösicke, H., Lentze, M. J., & Kunz, C. (2006) · Glycobiology · doi:10.1093/glycob/cwj092 · Cited by 77
Congenital disorders involving defective N-glycosylation of proteins
Schachter, H. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000923 · Cited by 84
Koehler, K., Malik, M., Mahmood, S., Gießelmann, S., Beetz, C., Hennings, J. C., Huebner, A. K., Grahn, A., Reunert, J., Nürnberg, G., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.08.002 · Cited by 89
“In MPI-CDG, GDPmannose is depleted and can be corrected by external mannose supplementation.(19) PMM2-CDG is caused by mutations in PMM2 (MIM 601785) and is the most frequent subtype of the glycosylation disorders.”
BackgroundSelf-citationRedefined genomic architecture in 15q24 directed by patient deletion/duplication breakpoint mapping
El-Hattab, A. W., Smolarek, T. A., Walker, M. E., Schorry, E. K., Immken, L. L., Patel, G., Abbott, M.-A., Lanpher, B. C., Ou, Z., Kang, S.-H. L., et al. (2009) · Human Genetics · doi:10.1007/s00439-009-0706-x · Cited by 76
“…(Pasutto et al. 2007), the cholesterol side chain cleavage enzyme gene (CYP11A1) associated with lipoid congenital adrenal hyperplasia (Tajima et al. 2001), and the mannose phosphate isomerase gene (MPI) that is associated with congenital disorder of glycosylation type Ib (Niehues et al. 1998).”
BackgroundThe Metabolic Origins of Mannose in Glycoproteins
Ichikawa, M., Scott, D. A., Losfeld, M., & Freeze, H. H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.544064 · Cited by 79
“6 g of mannose/kg/day as dietary supplements, raising their plasma mannose concentration by 3– 4-fold (4).”
BackgroundSelf-citationA Clinical Approach to Inherited Metabolic Diseases
Saudubray, J., Desguerre, I., Sedel, F., & Charpentier, C. (2006) · Springer eBooks · doi:10.1007/978-3-540-28785-8_1 · Cited by 76
The congenital disorders of glycosylation: A multifaceted group of syndromes
Eklund, E. A., & Freeze, H. H. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.01.012 · Cited by 81
Self-citationChen, S., Zhou, S., Sarkar, M., Spence, A. M., & Schachter, H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.288 · Cited by 72
Carbohydrate-Deficient Glycoprotein Syndromes: Inborn Errors of Protein Glycosylation
Keir, G., WINCHESTER, B. G., & Clayton, P. T. (1999) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456329903600103 · Cited by 75
Lenz, D., McClean, P., Kansu, A., Bonnen, P. E., Ranucci, G., Thiel, C., Straub, B. K., Harting, I., Alhaddad, B., Dimitrov, B., et al. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.260 · Cited by 76
“focusing of serum transferrin and ApoCIII were performed as described previously.27,28 Brefeldin A (BFA) assay - immunofluorescense— BFA assay (with concentration of 2.5 µg/ml BFA) to investigate the retrograde transport was performed as described previously.29 ER stress analyses— ER stress was…”
InfluentialČechová, A., Altassan, R., Borgel, D., Bruneel, A., Correia, J., Girard, M., Harroche, A., Kieć‐Wilk, B., Mohnike, K. L., Pascreau, T., et al. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12241 · Cited by 79
“Treatment of those symptoms should follow standard recommendations with no specifics for MPI-CDG.”
BackgroundInfluentialMammalian sugar‐binding receptors: known functions and unexplored roles
Taylor, M. E., & Drickamer, K. (2019) · FEBS Journal · doi:10.1111/febs.14759 · Cited by 76
Human disorders in N-glycosylation and animal models
Freeze, H. H. (2002) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00408-7 · Cited by 71
Self-citationMulti-allelic origin of congenital disorder of glycosylation (CDG)-Ic
Imbach, T., Grünewald, S., Schenk, B., Burda, P., Schollen, E., Wevers, R. A., Jaeken, J., de Klerk, J. B. C., Berger, E. G., Matthijs, G., et al. (2000) · Human Genetics · doi:10.1007/s004390000293 · Cited by 64
“By contrast, CDG-Ib is a hepatic-intestinal disease without or with only minor neurological involvement (Jaeken et al. 1998; Niehues et al. 1998).”
BackgroundJokela, T. A., Jauhiainen, M., Auriola, S. O. K., Kauhanen, M., Tiihonen, R., Tammi, M., & Tammi, R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706001200 · Cited by 80
Rush, J. S., Panneerselvam, K., Waechter, C. J., & Freeze, H. H. (2000) · Glycobiology · doi:10.1093/glycob/10.8.829 · Cited by 63
Self-citationImtiaz, F., Worthington, V., Champion, M., Beesley, C. E., Charlwood, J., Clayton, P. T., Keir, G., Mian, N., & WINCHESTER, B. G. (2000) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005669900330 · Cited by 64
“Mutations have been found in the PMI gene in these patients (Jaeken et al 1998 ; Niehues et al 1998).”
BackgroundInfluentialInborn errors presenting with liver dysfunction
Clayton, P. T. (2002) · Seminars in Neonatology · doi:10.1053/siny.2001.0086 · Cited by 62
Šagi, D., Kienz, P., Denecke, J., Marquardt, T., & Peter‐Katalinić, J. (2005) · PROTEOMICS · doi:10.1002/pmic.200401312 · Cited by 61
Self-citationThiel, C., Schwarz, M., Hasilik, M., Grieben, U. I., Hanefeld, F. A., Lehle, L., FIGURA, K. V., & Körner, C. (2002) · Biochemical Journal · doi:10.1042/bj20020794 · Cited by 64
Self-citation
Metadata
- Authors
- Niehues, R., Hasilik, M., Alton, G., Körner, C., Schiebe-Sukumar, M., Koch, H. G., Zimmer, K. P., Wu, R., Harms, E., Reiter, K., von Figura, K., Freeze, H. H., Harms, H. K., & Marquardt, T.
- Affiliations
- University Hospital Münster (DE)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- University of Göttingen (DE)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-04-01
- Volume
- 101
- Issue
- 7
- Pages
- 1414-1420
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508719
- OpenAlex
- W1970122244
- Cited by
- 422
- References
- 20
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 13 · 2023: 11 · 2022: 8 · 2021: 14 · 2020: 16 · 2019: 7 · 2018: 12 · 2017: 12 · 2016: 4 · 2015: 13 · 2014: 18 · 2013: 7 · 2012: 14
- FWCI
- 22.32
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01gm049096-04)
- National Institute of General Medical Sciences (R01 GM49096)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- protein-losing enteropathy, phosphomannomutase deficiency
- MeSH terms
- Cells, Cultured, Glycoproteins, Glycosylation, Humans, Infant, Male, Mannose, Mannose-6-Phosphate Isomerase, Mutation, Protein Processing, Post-Translational, Protein-Losing Enteropathies, Syndrome, Transferrin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.